Arcus Biosciences’ (RCUS) Buy Rating Reiterated at Mizuho

Share on StockTwits

Mizuho reaffirmed their buy rating on shares of Arcus Biosciences (NYSE:RCUS) in a research report released on Monday, AnalystRatings.com reports. Mizuho currently has a $22.00 price objective on the stock.

A number of other research firms also recently issued reports on RCUS. ValuEngine upgraded Arcus Biosciences from a hold rating to a buy rating in a report on Thursday, August 1st. Zacks Investment Research downgraded Arcus Biosciences from a buy rating to a hold rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $17.35.

Shares of NYSE:RCUS traded down $0.02 during mid-day trading on Monday, reaching $7.97. 54,579 shares of the stock were exchanged, compared to its average volume of 171,959. The company has a market cap of $366.42 million, a P/E ratio of -5.57 and a beta of 0.99. Arcus Biosciences has a one year low of $6.30 and a one year high of $13.77. The stock’s 50 day simple moving average is $8.33 and its 200-day simple moving average is $8.48.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.02). The firm had revenue of $1.75 million for the quarter, compared to the consensus estimate of $1.34 million. Arcus Biosciences had a negative return on equity of 38.73% and a negative net margin of 1,180.37%. As a group, research analysts forecast that Arcus Biosciences will post -2 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of RCUS. Aperio Group LLC bought a new position in shares of Arcus Biosciences during the second quarter worth about $32,000. Meeder Asset Management Inc. grew its stake in Arcus Biosciences by 672.9% in the third quarter. Meeder Asset Management Inc. now owns 4,939 shares of the company’s stock valued at $46,000 after purchasing an additional 4,300 shares in the last quarter. Susquehanna International Group LLP bought a new position in Arcus Biosciences in the second quarter valued at approximately $119,000. Athanor Capital LP bought a new position in Arcus Biosciences in the second quarter valued at approximately $126,000. Finally, Russell Investments Group Ltd. bought a new position in Arcus Biosciences in the second quarter valued at approximately $128,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

Recommended Story: What is quantitative easing?

Analyst Recommendations for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Gran Colombia Gold  Stock Price Crosses Above Two Hundred Day Moving Average of $4.78
Gran Colombia Gold Stock Price Crosses Above Two Hundred Day Moving Average of $4.78
AGF Management  Shares Cross Above 200 Day Moving Average of $5.56
AGF Management Shares Cross Above 200 Day Moving Average of $5.56
Endeavour Silver  Share Price Crosses Below 200-Day Moving Average of $2.99
Endeavour Silver Share Price Crosses Below 200-Day Moving Average of $2.99
Victrex  Downgraded by Zacks Investment Research to “Sell”
Victrex Downgraded by Zacks Investment Research to “Sell”
Regal Beloit Corp  Expected to Post Earnings of $1.25 Per Share
Regal Beloit Corp Expected to Post Earnings of $1.25 Per Share
$1.50 EPS Expected for ViacomCBS Inc.  This Quarter
$1.50 EPS Expected for ViacomCBS Inc. This Quarter


© 2006-2019 Ticker Report